Natera, Inc. (NTRA)
NASDAQ: NTRA · IEX Real-Time Price · USD
94.15
+1.27 (1.37%)
At close: May 1, 2024, 4:00 PM
93.94
-0.21 (-0.22%)
After-hours: May 1, 2024, 5:23 PM EDT
Natera Revenue
In the year 2023, Natera had annual revenue of $1.08B with 31.99% growth. Revenue in the quarter ending December 31, 2023 was $311.11M with 43.20% year-over-year growth.
Revenue (ttm)
$1.08B
Revenue Growth
+31.99%
P/S Ratio
10.29
Revenue / Employee
$328,749
Employees
3,293
Market Cap
11.22B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.08B | 262.35M | 31.99% |
Dec 31, 2022 | 820.22M | 194.74M | 31.13% |
Dec 31, 2021 | 625.49M | 234.48M | 59.97% |
Dec 31, 2020 | 391.01M | 88.68M | 29.33% |
Dec 31, 2019 | 302.33M | 44.67M | 17.34% |
Dec 31, 2018 | 257.65M | 48.03M | 22.91% |
Dec 31, 2017 | 209.63M | -2.89M | -1.36% |
Dec 31, 2016 | 212.51M | 22.16M | 11.64% |
Dec 31, 2015 | 190.36M | 31.07M | 19.50% |
Dec 31, 2014 | 159.29M | 104.12M | 188.72% |
Dec 31, 2013 | 55.17M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Tenet Healthcare | 20.56B |
Universal Health Services | 14.28B |
Solventum | 8.20B |
Smith & Nephew | 5.55B |
Charles River Laboratories International | 4.13B |
Incyte | 3.70B |
Bruker | 2.96B |
Exact Sciences | 2.50B |
NTRA News
- 2 hours ago - Natera to Report its First Quarter 2024 Results on May 9 - Business Wire
- 11 hours ago - Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage - Business Wire
- 9 days ago - Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications - Business Wire
- 20 days ago - Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation - Business Wire
- 23 days ago - Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients - Business Wire
- 26 days ago - Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer - Business Wire
- 4 weeks ago - Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer - Business Wire
- 6 weeks ago - Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer - Business Wire